Search results for "Expression"

showing 10 items of 5168 documents

Nitric oxide synthase: expression and expressional control of the three isoforms.

1995

Three isozymes of nitric oxide synthase (NOS) have been identified. Their cDNA- and protein structures as well as their genomic DNA structures have been described. NOS I (ncNOS, originally discovered in neurons) and NOS III (ecNOS, originally discovered in endothelial cells) are low output, Ca(2+)-activated enzymes whose physiological function is signal transduction. NOS II (iNOS, originally discovered in cytokine-induced macrophages) is a high output enzyme which produces toxic amounts of NO that represent an important component of the antimicrobial, antiparasitic and antineoplastic activity of these cells. Depending on the species, NOS II activity is largely (human) or completely (mouse a…

PharmacologyGene isoformRegulation of gene expressionchemistry.chemical_classificationMessenger RNAbiologyChromosome MappingPromoterGeneral MedicineIsozymeMolecular biologyGene Expression Regulation EnzymologicRatsNitric oxide synthaseIsoenzymesMiceEnzymechemistryBiochemistrybiology.proteinTranscriptional regulationAnimalsHumansNitric Oxide SynthasePromoter Regions GeneticNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Inhibiting proliferation in KB cancer cells by RNA interference-mediated knockdown of nicotinamide N-methyltransferase expression.

2011

The enzyme Nicotinamide N-methyltransferase (NNMT) catalyzes the methylation of nicotinamide and other pyridines, playing a pivotal role in the biotransformation and detoxification of many drugs and xenobiotic compounds. Several tumours have been associated with abnormal NNMT expression, however its role in tumour development remains largely unknown. In this study we investigated expression levels of Nicotinamide N-methyltransferase in a cancer cell line and we evaluated the effect of shRNA-mediated silencing of NNMT on cell proliferation. Cancer cells were examined for NNMT expression by semiquantitative RT-PCR and Western blot analysis. A HPLC-based catalytic assay was performed to asses…

PharmacologyGene knockdownCell growthReverse Transcriptase Polymerase Chain ReactionImmunologyBlotting WesternNNMTNicotinamide N-methyltransferaseTransfectionBiologytumor cellMolecular biologyKB CellsSmall hairpin RNABlotGene expressionCancer cellsilencingNicotinamide N-Methyltransferasegene expressionImmunology and AllergyHumanscell growthRNA InterferenceCell Proliferation
researchProduct

Genetics of the variable expression of CYP3A in humans.

2004

CYP3A isozymes participate in the metabolism of 45-60% of currently used drugs and of a variety of other compounds such as steroid hormones, toxins, and carcinogens. The CYP3A expression status is a major determinant of drug efficacy and safety, and it may also affect an individual's predisposition to certain cancers. The inter- and intraindividual expression of CYP3A is variable because of a complex interplay between genetic and environmental factors. Markers predictive of the individual CYP3A activity could improve therapies with CYP3A substrates by personalised dose adjustments, but their development has been slower than for other drug-metabolizing enzymes. Here we summarize the recent p…

PharmacologyGeneticsRegulation of gene expressionPolymorphism GeneticCYP3A4GenomicsOxidoreductases N-DemethylatingBiologyIsozymeGene Expression Regulation EnzymologicVariable ExpressionPharmaceutical PreparationsOrgan SpecificityCytochrome P-450 CYP3ACytochrome P-450 CYP3AHumansPharmacology (medical)PharmacokineticsAryl Hydrocarbon HydroxylasesCYP3A5HormoneTherapeutic drug monitoring
researchProduct

Murine embryonic stem cell line CGR8 expresses all subtypes of muscarinic receptors and multiple nicotinic receptor subunits: Down-regulation of α4- …

2015

Non-neuronal acetylcholine mediates its cellular effects via stimulation of the G-protein-coupled muscarinic receptors and the ligand-gated ion channel nicotinic receptors. The murine embryonic stem cell line CGR8 synthesizes and releases non-neuronal acetylcholine. In the present study a systematic investigation of the expression of nicotinic receptor subunits and muscarinic receptors was performed, when the stem cells were grown in the presence or absence of LIF, as the latter condition induces early differentiation. CGR8 cells expressed multiple nicotinic receptor subtypes (α3, α4, α7, α9, α10, β1, β2, β3, β4, γ, δ, e) and muscarinic receptors (M1, M3, M4, M5); M2 was detected only in 2 …

PharmacologyImmunologyMuscarinic acetylcholine receptor M3Down-RegulationMuscarinic acetylcholine receptor M2Cell DifferentiationMuscarinic acetylcholine receptor M1BiologyReceptors NicotinicReceptors MuscarinicCell biologyCell LineMiceProtein SubunitsNicotinic agonistGanglion type nicotinic receptorGene Expression RegulationMuscarinic acetylcholine receptor M5Muscarinic acetylcholine receptorImmunology and AllergyAnimalsAlpha-4 beta-2 nicotinic receptorEmbryonic Stem CellsInternational immunopharmacology
researchProduct

Recent progress in revealing the biological and medical significance of the non-neuronal cholinergic system.

2015

This special issue of International Immunopharmacology is the proceedings of the Fourth International Symposium on Non-neuronal Acetylcholine that was held on August 28-30, 2014 at the Justus Liebig University of Giessen in Germany. It contains original contributions of meeting participants covering the significant progress in understanding of the biological and medical significance of the non-neuronal cholinergic system extending from exciting insights into molecular mechanisms regulating this system via miRNAs over the discovery of novel cholinergic cellular signaling circuitries to clinical implications in cancer, wound healing, immunity and inflammation, cardiovascular, respiratory and …

PharmacologyInflammationWound HealingStem CellseducationImmunologyRespiratory Tract DiseasesBiologyImmunopharmacologyAcetylcholineMicroRNAsGene Expression RegulationCardiovascular DiseasesNeoplasmsImmunologyCholinergic systemImmunology and AllergyCholinergicAnimalsNeuroscienceSignal TransductionInternational immunopharmacology
researchProduct

Effects of Glyburide-Cyclosporin A Interaction on Interleukin-2 Production in Rats1

1999

The effects of simultaneous administrations of Cyclosporin A (CsA) and Glyburide on the immune system of rats has been evaluated in terms of Interleukin-2 (IL-2) production by Concanavalin A (ConA) stimulated splenocytes and exogenous IL-2 binding capacity. The inhibitory effect of Cyclosporin A on IL-2 production of lymphoid cells is well known. Spleen cells from rats receiving CsA had reduced levels of IL-2 when compared to untreated controls or rats receiving Glyburide only. Splenocytes from rats receiving both drugs had reduced levels of IL-2 when they were sacrificed 24 hours after one or three CsA administrations; instead when the animals were sacrificed 6 days after three CsA adminis…

PharmacologyInterleukin 2biologybusiness.industryReceptor expressionmedicine.medical_treatmentImmunologyGeneral MedicinePharmacologyToxicologyGlibenclamideImmune systemCytokineConcanavalin ACyclosporin aSplenocytemedicinebiology.proteinImmunology and Allergybusinessmedicine.drugImmunopharmacology and Immunotoxicology
researchProduct

Cytokine induction of NO synthase II in human DLD-1 cells: roles of the JAK-STAT, AP-1 and NF-κB-signaling pathways

1998

1. In human epithelial-like DLD-I cells, nitric oxide synthase (NOS) II expression was induced by interferon-gamma (100 u ml(-1)) alone and, to a larger extent, by a cytokine mixture (CM) consisting of interferon-gamma, interleukin-1beta (50 u ml(-1)) and tumor necrosis factor-alpha (10 ng ml(-1)). 2. CM-induced NOS II expression was inhibited by tyrphostin B42 (mRNA down to 1%; nitrite production down to 0.5% at 300 microM) and tyrphostin A25 (mRNA down to 24%, nitrite production down to 1% at 200 microM), suggesting the involvement of janus kinase 2 (JAK-2). Tyrphostin B42 also blocked the CM-induced JAK-2 phosphorylation (kinase assay) and reduced the CM-stimulated STAT1alpha binding act…

PharmacologyJanus kinase 2biologyKinaseOkadaic acidMolecular biologyNitric oxide synthasechemistry.chemical_compoundPyrrolidine dithiocarbamatechemistryGene expressionbiology.proteinPhenylarsine oxideAnisomycinBritish Journal of Pharmacology
researchProduct

Autoimmune biomarkers in glaucoma patients.

2013

There is growing evidence showing an autoimmune involvement in the pathogenesis of glaucoma, and that alterations in natural occurring autoantibody levels play a key role. The upregulation of autoantibodies can be associated with fatal conditions, but several studies demonstrate that natural autoantibodies entail also protective characteristics and influence the protein expression of neuroretinal cells. A disbalance of natural occurring autoantibodies may shift the physiological equilibrium of protective immunity leading to a predisposition for developing glaucoma. This article highlights recent advances in understanding of autoimmune mechanisms in the pathogenesis of glaucoma.

PharmacologyProtective immunitybusiness.industryAutoantibodyGlaucomaAutoimmunityGlaucomamedicine.diseaseProtein expressionPathogenesisDownregulation and upregulationDrug DiscoveryImmunologyProtective characteristicsmedicineAnimalsHumansbusinessBiomarkersAutoantibodiesCurrent opinion in pharmacology
researchProduct

Transcriptional regulation and expression of CYP3A4 in hepatocytes.

2007

CYP3A4 is the most abundantly expressed drug-metabolizing P450 enzyme in human liver and contributes to the metabolism of a large number of drugs in use today. CYP3A4 is constitutively expressed in adult hepatocytes but it can also be transcriptionally induced by a variety of structurally diverse xenochemicals. CYP3A4 strongly contributes to the important variability in the therapeutic and toxic effects of drugs owing to the major role it plays in xenobiotic metabolism and the large intra- and inter-individual variability to which it is subjected. The functional examination of up to 13 kb of the CYP3A4 5'-flanking region has revealed that the regulation of this gene is a complex issue, with…

PharmacologyRegulation of gene expressionPregnane X receptorTranscription GeneticClinical BiochemistryDown-RegulationBiologyPharmacologyRegulatory Sequences Nucleic AcidGene Expression Regulation EnzymologicCell biologyDrug developmentNuclear receptorCytochrome P-450 Enzyme SystemLiverRegulatory sequenceTranscriptional regulationHepatocytesAnimalsCytochrome P-450 CYP3AHumansTranscription factorDrug metabolismCurrent drug metabolism
researchProduct

The carbon monoxide-releasing molecule CORM-2 inhibits the inflammatory response induced by cytokines in Caco-2 cells

2007

Background and purpose: Recent evidence indicates that carbon monoxide-releasing molecules (CO-RMs) exhibit potential anti-inflammatory properties. In the present study, we have investigated whether tricarbonyl dichloro ruthenium(II) dimer (CORM-2) can control the inflammatory response induced by cytokines in a human colonic epithelial cell line, Caco-2. Experimental approach: Caco-2 cells were preincubated with CORM-2 for 30 minutes and then stimulated with interleukin (IL)-1β, tumor necrosis factor-α and interferon-γ for different times. Gene expression was analyzed by real-time PCR. Protein expression was investigated by Western blot and ELISA. Transcription factor activation was determi…

PharmacologySmall interfering RNACytokinep38 mitogen-activated protein kinasesEnhancer bindingmedicine.medical_treatmentGene expressionmedicineTumor necrosis factor alphaBiologyNFKB1Protein kinase AMolecular biologyBritish Journal of Pharmacology
researchProduct